drugset / Trial / NCT05549921
Phase II Study of TAEST16001 in Soft Tissue Sarcoma
Phase 2
Terminated
8 enrolled
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this trial is to evaluate the efficacy and safety of TAEST16001 cells in the treatment of advanced soft tissue sarcoma patients with HLA-A\*02:01 tissue genotype and positive tumor antigen NY-ESO-1 expression.
Timeline
- Start
- 2022-07-08
- Primary completion
- 2025-07-23
- Completion
- 2025-08-01
Outcome
Outcome not reported
Stopped: “The study was terminated due to initiation of a new clinical trial with an updated study design.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAEST16001 | Cell therapy | — | — |